A 3-year-old girl from Gujarat with β-thalassemia intermedia presents with severe bone pain and pathological fractures. Radiographs show cortical thinning and generalized osteopenia. What is the most common cause of bone disease in thalassemia patients?
A. Vitamin D deficiency from malabsorption
B. Extramedullary hematopoiesis and marrow expansion
C. Chronic hypoxia-induced osteoclast activation
D. Iron deposition in osteoblasts and osteocytes
Explanation
Bone Disease in Thalassemia: Pathophysiology
Key Point
Extramedullary hematopoiesis and massive bone marrow expansion are the most common cause of bone disease (thalassemic osteodystrophy) in thalassemia patients, particularly in thalassemia intermedia.
Mechanisms of Bone Pathology in Thalassemia
Loading diagram...
Comparative Pathophysiology of Bone Complications
Table
Mechanism
Prevalence
Severity
Reversibility
Timing
Marrow expansion + EMH
Most common
Moderate–severe
Partially reversible with transfusion
Early (by age 3–5)
Iron deposition
Common
Mild–moderate
Irreversible
Late (after age 10)
Chronic hypoxia
Contributory
Mild
Reversible with transfusion
Variable
Vitamin D deficiency
Less common
Mild
Reversible with supplementation
Variable
High-YieldNEET PG
Thalassemia intermedia patients have more severe bone disease than thalassemia major because they maintain higher hemoglobin levels (less transfusion), leading to sustained erythropoietin stimulation and prolonged marrow expansion.
Clinical Pearl
Bone marrow expansion causes:
Cortical thinning and widening of medullary cavity
Pathological fractures (especially vertebrae and femoral neck)
Spinal cord compression from extramedullary hematopoiesis
Why Iron Deposition Is Secondary
While iron deposition in osteoblasts and osteocytes does contribute to bone dysfunction (by impairing osteoblast function and increasing osteoclast activity), it is a later and less frequent cause than marrow expansion. Iron-induced bone disease typically manifests after age 10–15 in heavily transfused patients.
Management Implications
Transfusion therapy (in thalassemia intermedia) suppresses EPO and reduces marrow expansion
Hydroxyurea (in thalassemia intermedia) increases fetal hemoglobin and reduces hemolysis
Iron chelation prevents late iron-induced osteodystrophy
Calcium and vitamin D supplementation are adjunctive
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.